SCHEMBL348786

SCHEMBL348786

O=C(CC(=O)Oc1c(Cl)cc(Cl)cc1Cl)Oc1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ACLY P53396 1/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ABCB1 P08183 1/20 0.37
AKR1C4 P17516 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14305007 0.91 RAPGEF4 (0.41) ALDH1A1KDM4EGAAMAPTTSHR
SCHEMBL14311187 0.91 CA1 (0.35) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL8525341 0.90 TDP1 (0.40) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL14554131 0.89 KDM4E (0.47) ALDH1A1KDM4EGAAMAPTL3MBTL1
SCHEMBL4642299 0.85 ALDH1A1 (0.41) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL4642241 0.85 CA1 (0.39) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL4641646 0.83 CA1 (0.38) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL10981786 0.82 CYP1A2 (0.45) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL4642147 0.82 CA1 (0.37) CA1CA2CA9ALDH1A1KDM4E
SCHEMBL4642224 0.82 VCAM1 (0.40) CA1CA2CA9ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684309-A Near infrared frequency up-conversion fluorescent probe, benzopyrylium salt compound and preparation method and application thereof 安徽大学 2025-03-25 CN claimed
CN-112939970-A Pyridopyrimidinone derivative, preparation method thereof and application thereof in antitumor drugs 林剑雄 2021-06-11 CN claimed
EP-1751122-B1 MONOMER 5,6-DIPHENYL-1,2,4-TRIAZINIC DERIVATIVES AND THE USE THEREOF FABRE PIERRE DERMO COSMETIQUE (FR) 2010-03-17 EP claimed
US-20080299055-A1 Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof PIERRE FABRE DERMO-COSMETIQUE (FR) 2008-12-04 US claimed
US-20260132129-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER GENESIS THERAPEUTICS INC (US) 2026-05-14 US disclosed
US-20260078120-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2026-03-19 US disclosed
US-20260055099-A1 PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2026-02-26 US disclosed
WO-2025233837-A1 4H-PYRIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR USE AS NLRP3 INFLAMMASOME INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDER TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-11-13 WO disclosed
EP-4602043-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER Genesis Therapeutics, Inc. (US) 2025-08-20 EP disclosed
EP-4577544-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2025-07-02 EP disclosed
CN-119684309-B Near infrared frequency up-conversion fluorescent probe, benzopyrylium salt compound and preparation method and application thereof 安徽大学 2025-06-17 CN disclosed
US-20250188074-A1 PTPN11 INHIBITORS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-06-12 US disclosed
EP-0159707-B1 TRIAZOLOPYRIMIDINE DERIVATIVES DAIICHI SEIYAKU CO., LTD. (JP) 1990-01-24 EP disclosed
US-4866064-A AGRICULTURE HORTICULTURE KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1989-09-12 US disclosed
EP-0282635-A2 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1988-09-21 EP disclosed
EP-0279298-A1 Tricyclic triazolopyrimidine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1988-08-24 EP disclosed
EP-0242690-A2 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-one derivatives and agricultural-horticultural fungicide composition containing the same KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1987-10-28 EP disclosed
EP-0238059-A2 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1987-09-23 EP disclosed
US-4652646-A ANTIALLERGENS DAIICHI SEIYAKU CO., LTD. (JP) 1987-03-24 US disclosed
EP-0159707-A2 Triazolopyrimidine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1985-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188074-A1 PTPN11 INHIBITORS PTPRJ, PTPN11, PTPRF CA1 4817/4885CA2 3899/4885CA9 4253/4885
US-20080299055-A1 Monomer 5, 6-Diphenyl-1.2.4-Traizinic Derivatives and the Use Thereof POT1, TELO2, CLIC1 CA1 1532/4885CA2 674/4885CA9 1033/4885
US-20260132129-A1 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER PIK3R4, PIK3R1, PIK3R5 CA1 3844/4885CA2 2506/4885CA9 1720/4885
US-20260055099-A1 PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER KAT2A, KAT2B, KAT8 CA1 1959/4885CA2 3117/4885CA9 2033/4885
US-20260078120-A1 SUBSTITUTED PYRIDOPYRIMIDINONES CBR1, CBR3, CNR1 CA1 2773/4885CA2 1276/4885CA9 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.